Targeted pharmaceutical nanocarriers for cancer therapy and imaging (original) (raw)

Abstract

The use of various pharmaceutical nanocarriers has become one of the most important areas of nanomedicine. Ideally, such carriers should be specifically delivered (targeted) to the pathological area to provide the maximum therapeutic efficacy. Among the many potential targets for such nanocarriers, tumors have been most often investigated. This review attempts to summarize currently available information regarding targeted pharmaceutical nanocarriers for cancer therapy and imaging. Certain issues related to some popular pharmaceutical nanocarriers, such as liposomes and polymeric micelles, are addressed, as are different ways to target tumors via specific ligands and via the stimuli sensitivity of the carriers. The importance of intracellular targeting of drug- and DNA-loaded pharmaceutical nanocarriers is specifically discussed, including intracellular delivery with cell-penetrating peptides.

Keywords: Nanoparticles, nanocariers, targeted delivery, cancer therapy, imaging

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

References

• 1.Torchilin VP, editor. Nanoparticulates as Pharmaceutical Carriers. London, UK: Imperial College Press; 2006. [Google Scholar]
• 2.Müller RH. Colloidal carriers for controlled drug delivery and targeting: modification, characterization, and in vivo distribution. Stuttgart, Germany, and Boca Raton, FL: Wissenschaftliche Verlagsgesellschaft and CRC Press; 1991. [Google Scholar]
• 3.Cohen S, Bernstein H, editors. Microparticulate Systems for the Delivery of Proteins and Vaccines. New York, NY: Marcel Dekker; 1996. [Google Scholar]
• 4.Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600–1603. doi: 10.1126/science.8128245. [DOI] [PubMed] [Google Scholar]
• 5.Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46:169–185. doi: 10.1016/S0169-409X(00)00134-4. [DOI] [PubMed] [Google Scholar]
• 6.Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74:47–61. doi: 10.1016/S0168-3659(01)00309-1. [DOI] [PubMed] [Google Scholar]
• 7.Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: moledular size dependence and cutoff size. Cancer Res. 1995;55:3752–3756. [PubMed] [Google Scholar]
• 8.Lasic DD, Martin FJ. Stealth Liposomes. Boca Raton, FL: CRC Press; 1995. [Google Scholar]
• 9.Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev. 1995;16:141–155. doi: 10.1016/0169-409X(95)00022-Y. [DOI] [Google Scholar]
• 10.Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release. 2004;94:187–193. doi: 10.1016/j.jconrel.2003.10.008. [DOI] [PubMed] [Google Scholar]
• 11.Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284. doi: 10.1016/S0168-3659(99)00248-5. [DOI] [PubMed] [Google Scholar]
• 12.Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul. 1998;15:1–19. doi: 10.3109/02652049809006831. [DOI] [PubMed] [Google Scholar]
• 13.O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer. 2003;4:318–328. doi: 10.3816/cbc.2003.n.037. [DOI] [PubMed] [Google Scholar]
• 14.Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999;86:72–78. doi: 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
• 15.Perez AT, Domenech GH, Frankel C, Vogel CL. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest. 2002;20:22–29. doi: 10.1081/CNV-120014883. [DOI] [PubMed] [Google Scholar]
• 16.Schmidinger M, Wenzel C, Locker GJ, et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer. 2001;85:1850–1852. doi: 10.1054/bjoc.2001.2149. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 17.Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98:993–1001. doi: 10.1002/cncr.11593. [DOI] [PubMed] [Google Scholar]
• 18.Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003;21:167–176. doi: 10.1081/CNV-120016412. [DOI] [PubMed] [Google Scholar]
• 19.Harrington KJ, Lewanski C, Northcote AD, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer. 2001;37:2015–2022. doi: 10.1016/S0959-8049(01)00216-7. [DOI] [PubMed] [Google Scholar]
• 20.Johnston SR, Gore ME. Caelyx: phase II studies in ovarian cancer. Eur J Cancer. 2001;37:8–14. doi: 10.1016/S0959-8049(01)00329-X. [DOI] [PubMed] [Google Scholar]
• 21.Seiden MV, Muggia F, Astrow A, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004;93:229–232. doi: 10.1016/j.ygyno.2003.12.037. [DOI] [PubMed] [Google Scholar]
• 22.Lasic DD. Liposomes: From Physics to Applications. New York, NY: Elsevier; 1993. [Google Scholar]
• 23.Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160. doi: 10.1038/nrd1632. [DOI] [PubMed] [Google Scholar]
• 24.Torchilin VP. Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst. 1985;2:65–115. [PubMed] [Google Scholar]
• 25.Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987;3:123–193. [PubMed] [Google Scholar]
• 26.Torchilin VP, Narula J, Halpern E, Khaw BA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta. 1996;1279:75–83. doi: 10.1016/0005-2736(95)00248-0. [DOI] [PubMed] [Google Scholar]
• 27.Torchilin VP, Levchenko TS, Lukyanov AN, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta. 2001;1511:397–411. doi: 10.1016/S0005-2728(01)00165-7. [DOI] [PubMed] [Google Scholar]
• 28.Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26. doi: 10.1016/S0169-409X(00)00129-0. [DOI] [PubMed] [Google Scholar]
• 29.Fernandez AM, Van Derpoorten K, Dasnois L, et al. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem. 2001;44:3750–3753. doi: 10.1021/jm0108754. [DOI] [PubMed] [Google Scholar]
• 30.Yalkowsky SH, editor. Techniques of Solubilization of Drugs. New York, NY: M Dekker; 1981. [Google Scholar]
• 31.Shabner BA, Collings JM, editors. Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: JB Lippincott; 1990. [Google Scholar]
• 32.Yokogawa K, Nakashima E, Ishizaki J, et al. Relationships in the structure-tissue distribution of basic drugs in the rabbit. Pharm Res. 1990;7:691–696. doi: 10.1023/A:1015803202857. [DOI] [PubMed] [Google Scholar]
• 33.Hageluken A, Grunbaum L, Nurnberg B, et al. Lipophilic beta-adrenoceptor antagonists and local anesthetics are effective direct activators of G-proteins. Biochem Pharmacol. 1994;47:1789–1795. doi: 10.1016/0006-2952(94)90307-7. [DOI] [PubMed] [Google Scholar]
• 34.Torchilin VP, Weissig V. Polymeric micelles for delivery of poorly soluble drugs. In: Park K, Mrsny RJ, editors. Controlled Drug Delivery: Designing Technologies for the Future. Washington, DC: American Chemical Society; 2000. pp. 297–313. [Google Scholar]
• 35.Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev. 1995;16:295–309. doi: 10.1016/0169-409X(95)00031-2. [DOI] [Google Scholar]
• 36.Cammas S, Suzuki K, Sone C, et al. Thermo-responsive polymer nanoparticles with a core-shell micelle structure as site-specific drug carriers. J Control Release. 1997;48:157–164. doi: 10.1016/S0168-3659(97)00040-0. [DOI] [Google Scholar]
• 37.Le Garrec D, Taillefer J, Van Lier JE, et al. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J Drug Target. 2002;10:429–437. doi: 10.1080/1061186021000001887. [DOI] [PubMed] [Google Scholar]
• 38.Meyer O, Papahadjopoulos D, Leroux JC. Copolymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes. FEBS Lett. 1998;421:61–64. doi: 10.1016/S0014-5793(97)01520-2. [DOI] [PubMed] [Google Scholar]
• 39.Chung JE, Yokoyama M, Yamato M, et al. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate) J Control Release. 1999;62:115–127. doi: 10.1016/S0168-3659(99)00029-2. [DOI] [PubMed] [Google Scholar]
• 40.Stroh M, Zimmer JP, Duda DG, et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med. 2005;11:678–682. doi: 10.1038/nm1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 41.Trubetskoy VS, Torchilin VP. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Deliv Rev. 1995;16:311–320. doi: 10.1016/0169-409X(95)00032-3. [DOI] [Google Scholar]
• 42.Torchilin VP. How do polymers prolong circulation times of liposomes? J Liposome Res. 1996;9:99–116. doi: 10.3109/08982109609037204. [DOI] [Google Scholar]
• 43.Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207. doi: 10.1016/S0065-2571(00)00013-3. [DOI] [PubMed] [Google Scholar]
• 44.Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev. 1995;16:285–294. doi: 10.1016/0169-409X(95)00030-B. [DOI] [Google Scholar]
• 45.Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–237. doi: 10.1016/0014-5793(90)81016-H. [DOI] [PubMed] [Google Scholar]
• 46.Maruyama K, Yuda T, Okamoto A, et al. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem Pharm Bull (Tokyo) 1991;39:1620–1622. doi: 10.1248/cpb.39.1620. [DOI] [PubMed] [Google Scholar]
• 47.Senior J, Delgado C, Fisher D, et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1991;1062:77–82. doi: 10.1016/0005-2736(91)90337-8. [DOI] [PubMed] [Google Scholar]
• 48.Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066:29–36. doi: 10.1016/0005-2736(91)90246-5. [DOI] [PubMed] [Google Scholar]
• 49.Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 1991;88:11460–11464. doi: 10.1073/pnas.88.24.11460. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 50.Napper DH. Polymeric Stabilization of Colloidal Dispersions. New York, NY: Academic Press; 1983. [Google Scholar]
• 51.Woodle MC. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids. 1993;64:249–262. doi: 10.1016/0009-3084(93)90069-F. [DOI] [PubMed] [Google Scholar]
• 52.Allen TM. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1994;13:285–309. doi: 10.1016/0169-409X(94)90016-7. [DOI] [Google Scholar]
• 53.Chonn A, Semple SC, Cullis PR. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta. 1991;1070:215–222. doi: 10.1016/0005-2736(91)90167-7. [DOI] [PubMed] [Google Scholar]
• 54.Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem. 1992;267:18759–18765. [PubMed] [Google Scholar]
• 55.Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta. 1991;1070:187–192. doi: 10.1016/0005-2736(91)90162-2. [DOI] [PubMed] [Google Scholar]
• 56.Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;1103:94–100. doi: 10.1016/0005-2736(92)90061-P. [DOI] [PubMed] [Google Scholar]
• 57.Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta. 1992;1108:40–48. doi: 10.1016/0005-2736(92)90112-Y. [DOI] [PubMed] [Google Scholar]
• 58.Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994;1195:11–20. doi: 10.1016/0005-2736(94)90003-5. [DOI] [PubMed] [Google Scholar]
• 59.Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev. 1995;16:157–182. doi: 10.1016/0169-409X(95)00023-Z. [DOI] [Google Scholar]
• 60.Pang SNJ. Final report on the safety assessment of polyethylene glycols (PEGs)-6,-8,-32,-75,-150,-14M,-20M. J Am Coll Toxicol. 1993;12:429–457. [Google Scholar]
• 61.Powell GM. Polyethylene glycol. In: Davidson RL, editor. Handbook of Water-Soluble Gums and Resins. New York, NY: McGraw-Hill; 1980. pp. 1–31. [Google Scholar]
• 62.Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83:601–606. doi: 10.1002/jps.2600830432. [DOI] [PubMed] [Google Scholar]
• 63.Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22:405–417. doi: 10.1016/S0142-9612(00)00193-9. [DOI] [PubMed] [Google Scholar]
• 64.Torchilin VP. Strategies and means for drug targeting: an overview. In: Muzykantov VR, Torchilin VP, editors. Biomedical Aspects of Drug Targeting. Boston, MA: Kluwer Academic; 2002. pp. 3–26. [Google Scholar]
• 65.Krause HJ, Schwartz A, Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int J Pharm. 1985;27:145–155. doi: 10.1016/0378-5173(85)90064-X. [DOI] [Google Scholar]
• 66.Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16:215–233. doi: 10.1016/0169-409X(95)00026-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 67.Harper GR, Davies MC, Davis SS, et al. Steric stabilization of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cells in vitro. Biomaterials. 1991;12:695–700. doi: 10.1016/0142-9612(91)90119-U. [DOI] [PubMed] [Google Scholar]
• 68.Muller M, Voros J, Csues G, et al. Surface modification of PLGA microspheres. J Biomed Mater Res A. 2003;66A:55–61. doi: 10.1002/jbm.a.10502. [DOI] [PubMed] [Google Scholar]
• 69.Peracchia MT, Fattal E, Desmaele D, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999;60:121–128. doi: 10.1016/S0168-3659(99)00063-2. [DOI] [PubMed] [Google Scholar]
• 70.Calvo P, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res. 2001;18:1157–1166. doi: 10.1023/A:1010931127745. [DOI] [PubMed] [Google Scholar]
• 71.Bhadra D, Bhadra S, Jain S, Jain NKA. PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;257:111–124. doi: 10.1016/S0378-5173(03)00132-7. [DOI] [PubMed] [Google Scholar]
• 72.Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 1988;85:6949–6953. doi: 10.1073/pnas.85.18.6949. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 73.Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994;54:2186–2191. [PubMed] [Google Scholar]
• 74.Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–992. [PubMed] [Google Scholar]
• 75.Boman NL, Masin D, Mayer LD, et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994;54:2830–2833. [PubMed] [Google Scholar]
• 76.Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in avarian cancer. Oncologist. 2005;10:205–214. doi: 10.1634/theoncologist.10-3-205. [DOI] [PubMed] [Google Scholar]
• 77.Ewer MS, Martin FJ, Henderson C, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol. 2004;31:161–181. doi: 10.1053/j.seminoncol.2004.08.006. [DOI] [PubMed] [Google Scholar]
• 78.Allen TM, Hansen CB, de Menenez DEL. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev. 1995;16:267–284. doi: 10.1016/0169-409X(95)00029-7. [DOI] [Google Scholar]
• 79.Hwang KJ. Liposome pharamacokinetics. In: Ostro MJ, editor. Liposomes: From Biophysics to Therapeutics. New York, NY: Dekker; 1987. pp. 109–156. [Google Scholar]
• 80.Blume G, Cevc G, Crommelin MD, et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta. 1993;1149:180–184. doi: 10.1016/0005-2736(93)90039-3. [DOI] [PubMed] [Google Scholar]
• 81.Zalipsky S, Gittelman J, Mullah N. Biologically active ligand-bearing polymer-grafted liposomes. In: Gregoriadis G, editor. Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems. New York, NY: Plenum Press; 1998. pp. 131–139. [Google Scholar]
• 82.Torchilin VP, Rammohan R, Weissig V. PEG-Immunoliposomes: Attachment of Monoclonal Antibody to Distal Ends of PEG Chains Via p-Nnitrophenylcarbonyl Groups. Paper presented at: 27th International Symposium on Controlled Release of Bioactive Materials.; July 7–13. 2000; Paris, France. 2000
• 83.Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA. 2003;100:6039–6044. doi: 10.1073/pnas.0931428100. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 84.Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62:7190–7194. [PubMed] [Google Scholar]
• 85.Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74:95–113. doi: 10.1016/S0168-3659(01)00315-7. [DOI] [PubMed] [Google Scholar]
• 86.Kamps JA, Koning GA, Velinova MJ, et al. Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J Drug Target. 2000;8:235–245. doi: 10.3109/10611860008997902. [DOI] [PubMed] [Google Scholar]
• 87.Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumortargeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004;100:135–144. doi: 10.1016/j.jconrel.2004.08.007. [DOI] [PubMed] [Google Scholar]
• 88.Raffaghello L, Pagnan G, Pastorino F, et al. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett. 2003;197:151–155. doi: 10.1016/S0304-3835(03)00097-1. [DOI] [PubMed] [Google Scholar]
• 89.Marty C, Schwendener RA. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol Med. 2005;109:389–402. doi: 10.1385/1-59259-862-5:389. [DOI] [PubMed] [Google Scholar]
• 90.Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 2002;277:27135–27143. doi: 10.1074/jbc.M200429200. [DOI] [PubMed] [Google Scholar]
• 91.Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–1659. doi: 10.1016/j.addr.2004.02.014. [DOI] [PubMed] [Google Scholar]
• 92.Olivier JC, Huertas R, Lee HJ, et al. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002;19:1137–1143. doi: 10.1023/A:1019842024814. [DOI] [PubMed] [Google Scholar]
• 93.Kato K, Itoh C, Yosukouchi T, Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(ethylene glycol) derivatives. Biotechnol Prog. 2004;20:897–904. doi: 10.1021/bp0342093. [DOI] [PubMed] [Google Scholar]
• 94.Hatakeyama H, Akita H, Maruyama K, et al. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm. 2004;281:25–33. doi: 10.1016/j.ijpharm.2004.05.025. [DOI] [PubMed] [Google Scholar]
• 95.Ishida O, Maruyama K, Tanahashi H, et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res. 2001;18:1042–1048. doi: 10.1023/A:1010960900254. [DOI] [PubMed] [Google Scholar]
• 96.Derycke AS, De Witte PA. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol. 2002;20:181–187. [PubMed] [Google Scholar]
• 97.Gijsens A, Derycke A, Missiaen L, et al. Targeting of the photocytotoxic compound AIPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer. 2002;101:78–85. doi: 10.1002/ijc.10548. [DOI] [PubMed] [Google Scholar]
• 98.Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99:130–137. doi: 10.1002/ijc.10242. [DOI] [PubMed] [Google Scholar]
• 99.Joshee N, Bastola DR, Cheng PW. Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum Gene Ther. 2002;13:1991–2004. doi: 10.1089/10430340260355392. [DOI] [PubMed] [Google Scholar]
• 100.Xu L, Huang CC, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–346. [PubMed] [Google Scholar]
• 101.Tan PH, Manunta M, Ardjomand N, et al. Antibody targeted gene transfer to endothelium. J Gene Med. 2003;5:311–323. doi: 10.1002/jgm.358. [DOI] [PubMed] [Google Scholar]
• 102.Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA. 1996;93:14164–14169. doi: 10.1073/pnas.93.24.14164. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 103.Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA. 1991;88:5572–5576. doi: 10.1073/pnas.88.13.5572. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 104.Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269:3198–3204. [PubMed] [Google Scholar]
• 105.Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675–693. doi: 10.1016/S0169-409X(02)00042-X. [DOI] [PubMed] [Google Scholar]
• 106.Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56:1177–1192. doi: 10.1016/j.addr.2004.01.011. [DOI] [PubMed] [Google Scholar]
• 107.Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res. 2002;22:2131–2135. [PubMed] [Google Scholar]
• 108.Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptortargeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res. 2003;20:417–422. doi: 10.1023/A:1022656105022. [DOI] [PubMed] [Google Scholar]
• 109.Stephenson SM, Yang W, Stevens PJ, et al. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res. 2003;23:3341–3345. [PubMed] [Google Scholar]
• 110.Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Iummunother. 2002;51:153–162. doi: 10.1007/s00262-002-0266-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 111.Stella B, Arpicco S, Peracchia MT, et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci. 2000;89:1452–1464. doi: 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
• 112.Park EK, Lee SB, Lee YM. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials. 2005;26:1053–1061. doi: 10.1016/j.biomaterials.2004.04.008. [DOI] [PubMed] [Google Scholar]
• 113.Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553–1561. doi: 10.1016/S0142-9612(01)00267-8. [DOI] [PubMed] [Google Scholar]
• 114.Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol. 2004;11:996–1004. doi: 10.1016/j.acra.2004.04.018. [DOI] [PubMed] [Google Scholar]
• 115.Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137–172. doi: 10.1016/S0168-3659(01)00299-1. [DOI] [PubMed] [Google Scholar]
• 116.Nagasaki Y, Yasugi K, Yamamoto Y, et al. Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules. 2001;2:1067–1070. doi: 10.1021/bm015574q. [DOI] [PubMed] [Google Scholar]
• 117.Vinogradov S, Batrakova E, Li S, Kabanov A. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjugate Chem. 1999;10:851–860. doi: 10.1021/bc990037c. [DOI] [PubMed] [Google Scholar]
• 118.Leamon CP, Weigl D, Hendren RW. Folate copolymer-mediated transfection of cultured cells. Bioconjugate Chem. 1999;10:947–957. doi: 10.1021/bc990066n. [DOI] [PubMed] [Google Scholar]
• 119.Jule E, Nagasaki Y, Kataoka K. Lactose-installed poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug Chem. 2003;14:177–186. doi: 10.1021/bc025598+. [DOI] [PubMed] [Google Scholar]
• 120.Ogris M, Brunner S, Schuller S, et al. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 1999;6:595–605. doi: 10.1038/sj.gt.3300900. [DOI] [PubMed] [Google Scholar]
• 121.Dash PR, Read ML, Fisher KD, et al. Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J Biol Chem. 2000;275:3793–3802. doi: 10.1074/jbc.275.6.3793. [DOI] [PubMed] [Google Scholar]
• 122.Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today. 2001;6:44–51. doi: 10.1016/S1359-6446(00)01594-4. [DOI] [PubMed] [Google Scholar]
• 123.Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release. 2003;91:103–113. doi: 10.1016/S0168-3659(03)00239-6. [DOI] [PubMed] [Google Scholar]
• 124.Drummond DC, Hong K, Park JW, et al. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam Horm. 2000;60:285–332. doi: 10.1016/S0083-6729(00)60022-5. [DOI] [PubMed] [Google Scholar]
• 125.Dagar S, Krishnadas A, Rubinstein I, et al. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release. 2003;91:123–133. doi: 10.1016/S0168-3659(03)00242-6. [DOI] [PubMed] [Google Scholar]
• 126.Asai T, Shimizu K, Kondo M, et al. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 2002;520:167–170. doi: 10.1016/S0014-5793(02)02821-1. [DOI] [PubMed] [Google Scholar]
• 127.Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63:3154–3161. [PubMed] [Google Scholar]
• 128.Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer. 2004;108:780–789. doi: 10.1002/ijc.11615. [DOI] [PubMed] [Google Scholar]
• 129.Matsuda I, Konno H, Tanaka T, Nakamura S. Antimetastatic effect of hepatotropic liposomal adriamycin on human metastatic liver tumors. Surg Today. 2001;31:414–420. doi: 10.1007/s005950170132. [DOI] [PubMed] [Google Scholar]
• 130.Lee CM, Tanaka T, Murai T, et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiency suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002;62:4282–4288. [PubMed] [Google Scholar]
• 131.Opanasopit P, Sakai M, Nishikawa M, et al. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release. 2002;80:283–294. doi: 10.1016/S0168-3659(02)00006-8. [DOI] [PubMed] [Google Scholar]
• 132.Guo X, Szoka FC. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem. 2001;12:291–300. doi: 10.1021/bc000110v. [DOI] [PubMed] [Google Scholar]
• 133.Boomer JA, Thompson DH. Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem Phys Lipids. 1999;99:145–153. doi: 10.1016/S0009-3084(99)00033-X. [DOI] [PubMed] [Google Scholar]
• 134.Zalipsky S, Qazen M, Walker JA, et al. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem. 1999;10:703–707. doi: 10.1021/bc990031n. [DOI] [PubMed] [Google Scholar]
• 135.Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst. 1999;16:245–288. doi: 10.1615/critrevtherdrugcarriersyst.v16.i3.10. [DOI] [PubMed] [Google Scholar]
• 136.Zhang JX, Zalipsky S, Mullah N, et al. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol Res. 2004;49:185–198. doi: 10.1016/j.phrs.2003.09.003. [DOI] [PubMed] [Google Scholar]
• 137.Roux E, Francis M, Winnik FM, Leroux JC. Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs. Int J Pharm. 2002;242:25–36. doi: 10.1016/S0378-5173(02)00183-7. [DOI] [PubMed] [Google Scholar]
• 138.Simoes S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56:947–965. doi: 10.1016/j.addr.2003.10.038. [DOI] [PubMed] [Google Scholar]
• 139.Roux E, Passirani C, Scheffold S, et al. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Control Release. 2004;94:447–451. doi: 10.1016/j.jconrel.2003.10.024. [DOI] [PubMed] [Google Scholar]
• 140.Leroux J, Roux E, Le Garrec D, et al. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release. 2001;72:71–84. doi: 10.1016/S0168-3659(01)00263-2. [DOI] [PubMed] [Google Scholar]
• 141.Roux E, Stomp R, Giasson S, et al. Steric stabilization of liposomes by pH-responsive N-isopropylacrylamide copolymer. J Pharm Sci. 2002;91:1795–1802. doi: 10.1002/jps.10172. [DOI] [PubMed] [Google Scholar]
• 142.Sudimack JJ, Guo W, Tjarks W, Lee RJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta. 2002;1564:31–37. doi: 10.1016/S0005-2736(02)00399-1. [DOI] [PubMed] [Google Scholar]
• 143.Lee ES, Shin HJ, Na K, Bae YH. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release. 2003;90:363–374. doi: 10.1016/S0168-3659(03)00205-0. [DOI] [PubMed] [Google Scholar]
• 144.Turk MJ, Reddy JA, Chmielewski JA, Low PS. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta. 2002;1559:56–68. doi: 10.1016/S0005-2736(01)00441-2. [DOI] [PubMed] [Google Scholar]
• 145.Kakudo T, Chaki S, Futaki S, et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry. 2004;43:5618–5628. doi: 10.1021/bi035802w. [DOI] [PubMed] [Google Scholar]
• 146.Shi G, Guo W, Stephenson SM, Lee RJ. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Release. 2002;80:309–319. doi: 10.1016/S0168-3659(02)00017-2. [DOI] [PubMed] [Google Scholar]
• 147.Bae Y, Jang WD, Nishiyama N, et al. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol BioSyst. 2005;1:242–250. doi: 10.1039/b500266d. [DOI] [PubMed] [Google Scholar]
• 148.Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target. 2005;13:391–397. doi: 10.1080/10611860500376741. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 149.Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405–418. doi: 10.1016/j.jconrel.2004.12.018. [DOI] [PubMed] [Google Scholar]
• 150.Liu SQ, Tong YW, Yang YY. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions. Biomaterials. 2005;26:5064–5074. doi: 10.1016/j.biomaterials.2005.01.030. [DOI] [PubMed] [Google Scholar]
• 151.Sawant RM, Hurley JP, Salmaso S, et al. “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17:943–949. doi: 10.1021/bc060080h. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 152.Torchilin VP. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL: CRC Press; 1995. [Google Scholar]
• 153.Sullivan DC, Ferrari M. Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging. 2004;3:364–369. doi: 10.1162/1535350042973526. [DOI] [PubMed] [Google Scholar]
• 154.Morawski AM, Lanza GA, Wickline SA. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol. 2005;16:89–92. doi: 10.1016/j.copbio.2004.11.001. [DOI] [PubMed] [Google Scholar]
• 155.Tilcock C, Unger E, Cullis P, MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology. 1989;171:77–80. doi: 10.1148/radiology.171.1.2928549. [DOI] [PubMed] [Google Scholar]
• 156.Kabalka GW, Davis MA, Holmberg E, et al. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. Magn Reson Imaging. 1991;9:373–377. doi: 10.1016/0730-725X(91)90425-L. [DOI] [PubMed] [Google Scholar]
• 157.Phillips WT, Goins B. Targeted delivery of imaging agents by liposomes. In: Torchilin VP, editor. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL: CRC Press; 1995. pp. 149–173. [Google Scholar]
• 158.Tilcock C. Liposomal paramagnetic magnetic resonance contrast agents. In: Gregoriadis G, editor. Liposome Technology. Boca Raton, FL: CRC Press; 1993. pp. 65–87. [Google Scholar]
• 159.Schwendener RA, Wuthrich R, Duewell S, et al. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest Radiol. 1990;25:922–932. doi: 10.1097/00004424-199008000-00009. [DOI] [PubMed] [Google Scholar]
• 160.Torchilin VP, Trubetskoy VS. In vivo visualizing of organs and tissues with liposomes. J Liposome Res. 1995;5:795–812. doi: 10.3109/08982109509012682. [DOI] [Google Scholar]
• 161.Torchilin VP. Surface-modified liposomes in gamma- and MR-imaging. Adv Drug Deliv Rev. 1997;24:301–313. doi: 10.1016/S0169-409X(96)00472-3. [DOI] [Google Scholar]
• 162.Kabalka GW, Davis MA, Moss TH, et al. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med. 1991;19:406–415. doi: 10.1002/mrm.1910190231. [DOI] [PubMed] [Google Scholar]
• 163.Grant CW, Karlik S, Florio E. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med. 1989;11:236–243. doi: 10.1002/mrm.1910110211. [DOI] [PubMed] [Google Scholar]
• 164.Glogard C, Stensrud G, Hovland R, et al. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int J Pharm. 2002;233:131–140. doi: 10.1016/S0378-5173(01)00935-8. [DOI] [PubMed] [Google Scholar]
• 165.Torchilin VP. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol. 2000;1:183–215. doi: 10.2174/1389201003378960. [DOI] [PubMed] [Google Scholar]
• 166.Trubetskoy VS, Torchilin VP. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. J Liposomes Res. 1994;4:961–980. doi: 10.3109/08982109409018613. [DOI] [Google Scholar]
• 167.Torchilin VP. Novel polymers in microparticulate diagnostic agents. Chemetch. 1999;29:27–34. [Google Scholar]
• 168.Trubetskoy VS, Torchilin VP. Polyethyleneglycol based micelles as carriers of therapeutic and diagnostic agents. STP Pharma Sci. 1996;6:79–86. [Google Scholar]
• 169.Torchilin VP, Trubetskoy VS, Wolf GL. Magnetic resonance imaging of lymph nodes with GD-containing liposomes. In: Torchilin VP, editor. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL: CRC Press; 1995. pp. 403–413. [Google Scholar]
• 170.Patel HM, Boodle KM, Vaughan-Jones R. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta. 1984;801:76–86. doi: 10.1016/0304-4165(84)90214-9. [DOI] [PubMed] [Google Scholar]
• 171.Hlrano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci. 1985;74:915–921. doi: 10.1002/jps.2600740902. [DOI] [PubMed] [Google Scholar]
• 172.Unger EC, Winokur T, MacDougall P, et al. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology. 1989;171:81–85. doi: 10.1148/radiology.171.1.2928550. [DOI] [PubMed] [Google Scholar]
• 173.Torchilin VP, Trubetskoy VS, Narula J, Khaw BA. PEG-modified liposomes for gamma- and magnetic resonance imaging. In: Lasic DD, Martin FJ, editors. Stealth Liposomes. Boca Raton, FL: CRC Press; 1995. pp. 225–231. [Google Scholar]
• 174.Trubetskoy VS, Cannillo JA, Milshtein A, et al. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn Reson Imaging. 1995;13:31–37. doi: 10.1016/0730-725X(94)00083-F. [DOI] [PubMed] [Google Scholar]
• 175.Goins B, Phillips T. Radiolabeled liposomes for imaging and biodistribution studies. In: Torchilin VP, Weissig V, editors. Liposomes: A Practical Approach. London, UK: Oxford University Press; 2003. pp. 319–336. [Google Scholar]
• 176.Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Biodistribution and pharmacokinetics of 111 In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer. 2000;83:684–688. doi: 10.1054/bjoc.2000.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 177.Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Influence of tumour size on uptake of(111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer. 2000;83:684–688. doi: 10.1054/bjoc.2000.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 178.Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999;17:3512–3521. doi: 10.1200/JCO.1999.17.11.3512. [DOI] [PubMed] [Google Scholar]
• 179.Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243–254. [PubMed] [Google Scholar]
• 180.Stewart SS, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology. 1997;11:33–37. [Google Scholar]
• 181.Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer. 2000;83:1281–1286. doi: 10.1054/bjoc.2000.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 182.Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas—rationale for combination with radiotherapy. Acta Oncol. 2000;39:207–211. doi: 10.1080/028418600430789. [DOI] [PubMed] [Google Scholar]
• 183.Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res. 2000;6:2528–2537. [PubMed] [Google Scholar]
• 184.Bao A, Goins B, Klipper R, et al. Direct 99m Tc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther. 2003;308:419–425. doi: 10.1124/jpet.103.059535. [DOI] [PubMed] [Google Scholar]
• 185.Belhaj-Tayeb H, Briane D, Vergote J, et al. In vitro and in vivo study of 99m Tc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:502–509. doi: 10.1007/s00259-002-1038-4. [DOI] [PubMed] [Google Scholar]
• 186.Huh YM, Jun YW, Song HT, et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc. 2005;127:12387–12391. doi: 10.1021/ja052337c. [DOI] [PubMed] [Google Scholar]
• 187.Elbayoumi TA, Torchilin VP. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging. 2006;33:1196–1205. doi: 10.1007/s00259-006-0139-x. [DOI] [PubMed] [Google Scholar]
• 188.Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Anti-nucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res. 2007;17:1–14. doi: 10.1080/08982100601186474. [DOI] [PubMed] [Google Scholar]
• 189.Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm. 2006;62:235–240. doi: 10.1016/j.ejpb.2005.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 190.Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006;128:2115–2120. doi: 10.1021/ja057254a. [DOI] [PubMed] [Google Scholar]
• 191.Lin AW, Lewinski NA, West JL, et al. Optically tunable nanoparticle contrast agents for early cancer detection: model-based analysis of gold nanoshells. J Biomed Opt. 2005;10:064035–064044. doi: 10.1117/1.2141825. [DOI] [PubMed] [Google Scholar]
• 192.Derycke AS, de Witte PA. Liposomes for photodynamic therapy. Adv Drug Deliv Rev. 2004;56:17–30. doi: 10.1016/j.addr.2003.07.014. [DOI] [PubMed] [Google Scholar]
• 193.Takeuchi Y, Ichikawa K, Yonezawa S, et al. Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J Control Release. 2004;97:231–240. doi: 10.1016/j.jconrel.2004.03.030. [DOI] [PubMed] [Google Scholar]
• 194.Bourre L, Thibaut S, Fimiani M, et al. In vivo photosensitizing efficiency of a diphenylchlorin sensitizer: interest of a DMPC liposome formulation. Pharmacol Res. 2003;47:253–261. doi: 10.1016/S1043-6618(02)00312-2. [DOI] [PubMed] [Google Scholar]
• 195.Brignole C, Pagnan G, Marimpietri D, et al. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett. 2003;197:231–235. doi: 10.1016/S0304-3835(03)00107-1. [DOI] [PubMed] [Google Scholar]
• 196.Rubas W, Supersaxo A, Weder HG, et al. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer. 1986;37:149–154. doi: 10.1002/ijc.2910370123. [DOI] [PubMed] [Google Scholar]
• 197.Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm Res. 2003;20:423–428. doi: 10.1023/A:1022608321861. [DOI] [PubMed] [Google Scholar]
• 198.Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2006;78:7–14. doi: 10.1007/s11060-005-9059-z. [DOI] [PubMed] [Google Scholar]
• 199.Hilger I, Hiergeist R, Hergt R, et al. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Invest Radiol. 2002;37:580–586. doi: 10.1097/00004424-200210000-00008. [DOI] [PubMed] [Google Scholar]
• 200.Johannsen M, Thiesen B, Jordan A, et al. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate. 2005;64:283–292. doi: 10.1002/pros.20213. [DOI] [PubMed] [Google Scholar]
• 201.Johannsen M, Gneveckow U, Eckelt L, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia. 2005;21:637–647. doi: 10.1080/02656730500158360. [DOI] [PubMed] [Google Scholar]
• 202.Johannsen M, Thiesen B, Gneveckow U, et al. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate. 2006;66:97–104. doi: 10.1002/pros.20324. [DOI] [PubMed] [Google Scholar]
• 203.Ivkov R, DeNardo SJ, Daum W, et al. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res. 2005;11:7093s–7103s. doi: 10.1158/1078-0432.CCR-1004-0016. [DOI] [PubMed] [Google Scholar]
• 204.Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides. 1997;18:1431–1439. doi: 10.1016/S0196-9781(97)00242-8. [DOI] [PubMed] [Google Scholar]
• 205.Torchilin VP, editor. Immobilized Enzymes in Medicine. New York, NY: Springer-Verlag; 1991. [Google Scholar]
• 206.Torchilin VP, Zhou F, Huang L. pH-sensitive liposomes. J Liposome Res. 1993;3:201–255. [Google Scholar]
• 207.Sheff D. Endosomes as a route for drug delivery in the real world. Adv Drug Deliv Rev. 2004;56:927–930. doi: 10.1016/j.addr.2003.11.005. [DOI] [PubMed] [Google Scholar]
• 208.Asokan A, Cho MJ. Cytosolic delivery of macromolecules, II: mechanistic studies with pH-sensitive morpholine lipids. Biochim Biophys Acta. 2003;1611:151–160. doi: 10.1016/S0005-2736(03)00050-6. [DOI] [PubMed] [Google Scholar]
• 209.Shalaev EY, Steponkus PL. Phase diagram of 1,2-dioleoylphosphatidylethanolamine (DOPE): water system at subzero temperatures and at low water contents. Biochim Biophys Acta. 1999;1419:229–247. doi: 10.1016/S0005-2736(99)00068-1. [DOI] [PubMed] [Google Scholar]
• 210.Gaspar MM, Perez-Soler R, Cruz ME. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol. 1996;38:373–377. doi: 10.1007/s002800050497. [DOI] [PubMed] [Google Scholar]
• 211.Kisel MA, Kulik LN, Tsybovsky IS, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105–114. doi: 10.1016/S0378-5173(01)00579-8. [DOI] [PubMed] [Google Scholar]
• 212.Geisert EE, Del Mar NA, Owens JL, Holmberg EG. Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci Lett. 1995;184:40–43. doi: 10.1016/0304-3940(94)11163-D. [DOI] [PubMed] [Google Scholar]
• 213.Yessine MA, Leroux JC. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv Drug Deliv Rev. 2004;56:999–1021. doi: 10.1016/j.addr.2003.10.039. [DOI] [PubMed] [Google Scholar]
• 214.Chen G, Hoffman AS. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature. 1995;373:49–52. doi: 10.1038/373049a0. [DOI] [PubMed] [Google Scholar]
• 215.Bae Y, Nishiyama N, Fukushima S, et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem. 2005;16:122–130. doi: 10.1021/bc0498166. [DOI] [PubMed] [Google Scholar]
• 216.Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8:1188–1196. doi: 10.1038/sj.gt.3301506. [DOI] [PubMed] [Google Scholar]
• 217.Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target. 2005;13:73–80. doi: 10.1080/10611860400011935. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 218.Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell. 1988;55:1179–1188. doi: 10.1016/0092-8674(88)90262-0. [DOI] [PubMed] [Google Scholar]
• 219.Frankel AD, Pabo CO. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell. 1988;55:1189–1193. doi: 10.1016/0092-8674(88)90263-2. [DOI] [PubMed] [Google Scholar]
• 220.Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA. 1991;88:1864–1868. doi: 10.1073/pnas.88.5.1864. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 221.Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997;88:223–233. doi: 10.1016/S0092-8674(00)81843-7. [DOI] [PubMed] [Google Scholar]
• 222.Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci. 2000;21:45–48. doi: 10.1016/S0165-6147(99)01429-7. [DOI] [PubMed] [Google Scholar]
• 223.Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99–103. doi: 10.1016/S0165-6147(00)01447-4. [DOI] [PubMed] [Google Scholar]
• 224.Zaro JL, Shen WC. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem Biophys Res Commun. 2003;307:241–247. doi: 10.1016/S0006-291X(03)01167-7. [DOI] [PubMed] [Google Scholar]
• 225.Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev. 2005;57:579–596. doi: 10.1016/j.addr.2004.10.005. [DOI] [PubMed] [Google Scholar]
• 226.Rothbard JB, Jessop TC, Wender PA. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev. 2005;57:495–504. doi: 10.1016/j.addr.2004.10.003. [DOI] [PubMed] [Google Scholar]
• 227.Fawell S, Seery J, Daikh Y, et al. TAT-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA. 1994;91:664–668. doi: 10.1073/pnas.91.2.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 228.Kim DT, Mitchell DJ, Brockstedt DG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 1997;159:1666–1668. [PubMed] [Google Scholar]
• 229.Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569–1572. doi: 10.1126/science.285.5433.1569. [DOI] [PubMed] [Google Scholar]
• 230.Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kipl induces cell migration. Nat Med. 1998;4:1449–1452. doi: 10.1038/4042. [DOI] [PubMed] [Google Scholar]
• 231.Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev. 2005;57:559–577. doi: 10.1016/j.addr.2004.12.001. [DOI] [PubMed] [Google Scholar]
• 232.Roeder GE, Parish JL, Stern PL, Gaston K. Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammlian cells and induce apoptotic cell death. Biotechnol Appl Biochem. 2004;40:157–165. doi: 10.1042/BA20030172. [DOI] [PubMed] [Google Scholar]
• 233.Liu CS, Kong B, Xia HH, et al. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med. 2001;3:145–152. doi: 10.1002/jgm.164. [DOI] [PubMed] [Google Scholar]
• 234.Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998;16:440–443. doi: 10.1038/nbt0598-440. [DOI] [PubMed] [Google Scholar]
• 235.Zavaglia D, Normand N, Brewis N, et al. VP22-mediated and light-activated delivery of an anti-c-rafl antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol Ther. 2003;8:840–845. doi: 10.1016/j.ymthe.2003.08.001. [DOI] [PubMed] [Google Scholar]
• 236.Tasciotti E, Zoppe M, Giacca M. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther. 2003;10:64–74. doi: 10.1038/sj.cgt.7700526. [DOI] [PubMed] [Google Scholar]
• 237.Nori A, Jensen KD, Tijerina M, et al. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem. 2003;14:44–50. doi: 10.1021/bc0255900. [DOI] [PubMed] [Google Scholar]
• 238.Nori A, Jensen KD, Tijerina M, et al. Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. J Control Release. 2003;91:53–59. doi: 10.1016/S0168-3659(03)00213-X. [DOI] [PubMed] [Google Scholar]
• 239.Vocero-Akbani A, Lissy NA, Dowdy SF. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol. 2000;322:508–521. doi: 10.1016/S0076-6879(00)22046-6. [DOI] [PubMed] [Google Scholar]
• 240.Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol. 2002;120:1341–1346. doi: 10.1001/archopht.120.10.1341. [DOI] [PubMed] [Google Scholar]
• 241.Shokolenko IN, Alexeyev MF, LeDoux SP, Wilson GL. TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair (Amst) 2005;4:511–518. doi: 10.1016/j.dnarep.2004.11.009. [DOI] [PubMed] [Google Scholar]
• 242.Parada Y, Banerji L, Glassford J, et al. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kipl expression. J Biol Chem. 2001;276:23572–23580. doi: 10.1074/jbc.M101885200. [DOI] [PubMed] [Google Scholar]
• 243.Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol. 2002;62:864–872. doi: 10.1124/mol.62.4.864. [DOI] [PubMed] [Google Scholar]
• 244.Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol. 2002;168:2393–2401. doi: 10.4049/jimmunol.168.5.2393. [DOI] [PubMed] [Google Scholar]
• 245.Wang HY, Fu T, Wang G, et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest. 2002;109:1463–1470. doi: 10.1172/JCI15399. [DOI] [PMC free article] [PubMed] [Google Scholar]